![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Completes Enrollment of Second Cohort in Phase 2 Study of MM-121 in Non-Small Cell Lung Cancer
April 29, 2013 08:36 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 29, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in the second cohort of a randomized,...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Completes Enrollment of One Cohort in Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer
April 15, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in one group of a two-cohort randomized Phase...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Webcast of Inaugural Research & Development Day
April 05, 2013 12:11 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 5, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will hold its inaugural Research & Development Day for analysts and the...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Paclitaxel in Patients With Platinum-Resistant or Refractory Advanced Ovarian Cancers
March 18, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., March 18, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2, open-label, randomized clinical...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Reports Fourth Quarter and Full Year 2012 Financial Results
March 14, 2013 08:00 ET
|
Merrimack Pharmaceuticals
Enters 2013 With Six Novel Therapeutic Candidates in Clinical Development, Including Phase 3 and Phase 2 Trials in Multiple Cancer Indications
Progress Made in 2012 Puts Merrimack in Position for...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2012 Investor Conference Call
February 27, 2013 09:14 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2012 Investor Conference Call and...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack to Present at the Cowen and Company 33rd Annual Health Care Conference
February 25, 2013 12:31 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Cowen and...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack to Participate in Pancreatic Cancer Panel at the 2013 BIO CEO & Investor Conference
February 07, 2013 12:42 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Peter Laivins, Vice President of Late Stage Clinical Development and Project...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers
January 23, 2013 08:19 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that preclinical data regarding the bispecific antibody MM-111 will be presented at...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Initiates Cross-Tumor Study to Investigate Potential Predictive Response Markers for a Developmental Nanotherapeutic Chemotherapy
December 19, 2012 14:11 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 19, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a cross indication translational study. The study...